aspartimide is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-05-11. Where a claim depends on a specific study, the study is described rather than over-claimed.
Documentation accompanying research peptides usually includes a certificate of analysis listing the batch number, purity figure, and test methods applied. Buyers comparing suppliers should check whether the reported purity refers to chromatographic area or to a mass-balance calculation, because the two are not equivalent. Counter-ion content, residual solvents, and water content are sometimes omitted from such certificates even though they affect the actual peptide mass present. Independent verification through a second laboratory is the most direct way to confirm that a supplied material matches its label.
Purity assessment of peptide reagents normally relies on reversed-phase high-performance liquid chromatography. A gradient of acetonitrile in water with trifluoroacetic acid, paired with a C18 stationary phase, separates the target tetrapeptide from truncated sequences and deletion analogues. Detection at 214 nanometres exploits absorbance of the peptide backbone, since the molecule contains no aromatic residue. Results are expressed as a percentage of total peak area. Values above ninety-five percent are typical for research-grade material, although reporting conventions vary between suppliers.
No pharmacopoeial monograph exists for this peptide, so quality rests on the supplier's internal specifications and on whatever independent testing a purchaser arranges. Certificates of analysis differ widely in which tests they report and in the limits applied. The counter-ion introduced during purification, commonly acetate or trifluoroacetate, changes the net peptide content of a given mass of powder, so two samples of equal weight may not contain equal amounts of the active sequence. Third-party laboratories can verify purity, identity, residual solvents, and counter-ion content for a fee, which makes documentation more informative than labelling.
Verification of a sample usually begins with reversed-phase high-performance liquid chromatography, which resolves the peptide from truncated sequences and other impurities and expresses purity as a percentage of total peak area. Mass spectrometry by electrospray ionisation or matrix-assisted laser desorption supplies an independent check, because the measured mass can be compared against the theoretical value for AEDG. Amino acid analysis or tandem mass spectrometry sequencing can confirm residue order. Each of these methods answers a different question: a purity figure does not establish identity, and an identity match does not establish how much of the material is intact peptide.
The molecule is a short, linear, hydrophilic peptide that dissolves readily in water or aqueous buffer. Its principal chemical liabilities are hydrolytic rather than oxidative, since it contains no cysteine, methionine, or tryptophan residues. The aspartate–glycine step is a recognised site for aspartimide formation under mildly acidic or basic conditions, generating isoaspartate and succinimide-related products over time. Desiccated lyophilised powder held at −20 °C is comparatively stable, whereas dilute solutions degrade faster and are best frozen as single-use aliquots rather than thawed repeatedly.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Freeze-dried solid |
| Solubility class | Freely soluble in water | Aqueous buffers also suitable |
| Typical storage temperature | Minus 20 degrees Celsius or colder | Desiccated and light protected |
| Typical analytical method | RP-HPLC with UV detection | 214 nm on C18 column |
| Identity confirmation | Electrospray mass spectrometry | Sequence verified separately |
Human data are limited to small studies, often without the randomization, blinding, or control groups expected in contemporary clinical research. Reported outcomes have included changes in melatonin levels, immune markers, and subjective measures, but sample sizes were generally too small to support firm conclusions. Some reviews treat the peptide as promising while noting methodological weaknesses; others question whether the observed effects are specific. The compound is frequently discussed in longevity-focused communities, where enthusiasm often outpaces the published evidence. Separating established findings from speculation is therefore important when reading summaries of this research.
Epitalon emerged from research conducted in Saint Petersburg by Vladimir Khavinson and colleagues, who studied short peptides as potential regulators of aging. The work built on epithalamin, a pineal gland extract reported to influence neuroendocrine function. Epitalon was designed as a synthetic counterpart with a defined sequence, allowing reproducible experiments that extracts could not support. Early publications described effects on melatonin rhythms and lifespan in animal models. These findings circulated mainly in Russian-language journals during the 1990s, which limited their visibility among English-speaking researchers.
The most widely cited claim is that epitalon activates telomerase and thereby extends telomere length. Supporting evidence comes largely from cultured human cells, where treatment was associated with increased telomerase activity and delayed replicative senescence. Telomerase activation is a biologically consequential effect, since the enzyme is largely silenced in most somatic cells. However, the route by which a short peptide would reach and act on the enzyme's regulatory machinery has not been established. Independent replication in human trials is scarce, so the link between cell-culture observations and whole-body aging remains an open question.
Regulatory treatment differs by country. No formulation of epitalon holds a marketing authorisation as a medicine in the United States or the European Union, where material sold for laboratory use is handled as a research chemical and is not intended for human consumption. In Russia, several short peptide preparations from the same institute's peptide series are registered medicinal products, and epitalon appears in that national context. Elsewhere it is frequently offered as a cosmetic ingredient, a category with lighter requirements. Advertising claims about longevity or disease prevention are restricted in most jurisdictions, which limits how sellers describe the compound.
Freeze-dried epitalon is normally kept at minus twenty degrees Celsius in a sealed, desiccated container, protected from light. Short excursions at ambient temperature during shipping are generally tolerated, but repeated warming and cooling cycles encourage moisture uptake, which shortens shelf life. Once dissolved, the peptide is far less stable than the solid: aqueous solutions are subject to hydrolysis and to deamidation at the aspartate and glutamate residues. Working solutions are therefore held refrigerated and used within days, and repeated freezing and thawing of the same vial is best avoided.
Identity and purity are checked by reversed-phase high-performance liquid chromatography, usually with ultraviolet detection near 214 nanometres, where the peptide bond absorbs. Mass spectrometry confirms the expected mass and reveals whether truncation products or adducts are present. Acid hydrolysis followed by amino acid analysis gives the residue ratio, which should approximate one alanine, one glutamate, one aspartate and one glycine. Counter-ions such as acetate or trifluoroacetate remain in the dried product and lower net peptide content, so a stated purity figure on a label does not by itself describe how much peptide a vial holds.
No national medicines regulator has approved epitalon as a therapeutic product. It is generally distributed as a research chemical, and in some jurisdictions selling peptides for human consumption without approval is restricted or prohibited. Certificates of analysis accompanying commercial material vary in which tests are performed, and independent verification of identity and purity is uncommon. Statements about anti-ageing or disease-prevention benefits on vendor pages are marketing claims rather than regulatory findings, a distinction that shapes how the compound is discussed in scientific and popular sources alike.
The most frequently cited laboratory finding is that AEDG increased telomerase activity and extended telomere length in cultured human somatic cells. That work used fetal fibroblast strains and reported changes in enzyme activity alongside altered division counts. Replication by unrelated groups has been limited, and the published record is largely a single-laboratory series rather than a multi-centre programme. The result supports a hypothesis about peptide influence on gene expression in cell culture; it does not by itself establish an effect on telomere length in living animals or in people.
Animal and clinical reports appear mainly in Russian-language journals from the 1990s and 2000s, covering endpoints such as melatonin rhythm, lifespan in aged rodents, and retinal function. Many of these papers involve small groups, lack blinding or placebo comparison, and are difficult to retrieve through indexed databases. Review articles published in English generally summarise the claims without reanalysing the underlying data. Because no large randomised trial exists, the clinical importance of these reported effects stays unresolved and is properly described as an open question.
=== Sexual disorders === Persistent genital arousal disorder (PGAD) results in spontaneous, persistent, and uncontrollable genital arousal in women, unrelated to any feelings of sexual desire. Clitoral priapism is a rare, potentially painful medical condition and is sometimes described as an aspect of PGAD. With PGAD, arousal lasts for an unusually extended period (ranging from hours to days); it can also be associated with morphometric and vascular modifications of the clitoris. Drugs may cause or affect clitoral priapism. The drug trazodone is known to cause male priapism as a side effect, but there is only one documented report that it may have caused clitoral priapism, in which case discontinuing the medication may be a remedy. Additionally, nefazodone is documented to have caused clitoral engorgement, as distinct from clitoral priapism, in one case, and clitoral priapism can sometimes start as a result of, or only after, the discontinuation of antipsychotics or selective serotonin reuptake inhibitors (SSRIs). Because PGAD is relatively rare and, as its concept apart from clitoral priapism, has only been researched since 2001, there is little research into what may cure or remedy the disorder. In some recorded cases, PGAD was caused by or caused, a pelvic arterial-venous malformation with arterial branches to the clitoris; surgical treatment was effective in these cases.
==== Electron-detachment dissociation ==== Electron-detachment dissociation (EDD) is a method for fragmenting anionic species in mass spectrometry. It serves as a negative counter mode to electron capture dissociation. Negatively charged ions are activated by irradiation with electrons of moderate kinetic energy. The result is ejection of electrons from the parent ionic molecule, which causes dissociation via recombination.
Russia called for restraint from all parties involved in the Islamabad talks, urging them to adopt a "responsible approach" and avoid actions that could undermine the negotiations. In a statement reported by TASS, the Russian Foreign Ministry said the talks represent an opportunity to advance a settlement of the crisis in the Gulf region. The ministry added that most countries support the diplomatic process and expressed hope for the success of the United States–Iran talks being held in Islamabad under Pakistani mediation. It also noted concerns that "forces" may be attempting to slow or obstruct progress toward peace. France expressed support for the Islamabad talks and called for de-escalation. President Emmanuel Macron said that he had urged Iranian president Masoud Pezeshkian to use the negotiations to achieve a "lasting de-escalation" and work toward a broader agreement ensuring regional security. Macron also emphasized the need for Iran to restore freedom of navigation in the Strait of Hormuz as part of efforts to stabilize the region. Hamas welcomed the Islamabad talks, expressing support for efforts aimed at ending the conflict. In a statement reported by Al Jazeera, the group said it backed negotiations "aimed at a complete and comprehensive end" to the war involving the United States and its allies. The statement also expressed hope for the success of Pakistan’s mediation efforts, stating that positive outcomes could contribute to regional stability and unity among Arab and Islamic countries.
In February 2015, Stanford professor John Ioannidis wrote in the Journal of the American Medical Association that no peer-reviewed research from Theranos had been published in medical research literature. In May 2015, University of Toronto Professor Eleftherios Diamandis analyzed Theranos technology and concluded that "most of the company's claims are exaggerated". Attempting to boost the company's credibility, Holmes invited then–U.S. Vice President Joe Biden to tour their facility. Biden praised what he saw, but to conceal the lab's true operating conditions, Holmes and Balwani had created a fake lab for the Vice President's tour.
Chemical biology is a scientific discipline between the fields of chemistry and biology. The discipline involves the application of chemical techniques, analysis, and often small molecules produced through synthetic chemistry, to the study and manipulation of biological systems. Although often confused with biochemistry, which studies the chemistry of biomolecules and regulation of biochemical pathways within and between cells, chemical biology remains distinct by focusing on the application of chemical tools to address biological questions.
Sources: en.wikipedia.org
The initial therapeutic effects of atomoxetine usually take 1 to 4 weeks to become apparent. A further 2 to 4 weeks may be required for the full therapeutic effects to be seen. Incrementally increasing response may occur up to 1 year or longer. The maximum recommended total daily dose in children and adolescents is 70 mg and adults is 100 mg.
== Harvesting and processing == All ECM samples originate from mammalian tissues, such as dermis, pericardium, and small intestinal submucosa (SIS). After explantation from the source, the ECM biomaterial retains some characteristics of the original tissue. The ECM tissues can be harvested from varying stages in the developmental stages in mammalian species such as human, porcine, equine, and bovine. Although they are similarly composed of fibril collagen, the microstructure, specific composition (including presence of non-collagenous protein and glycosaminoglycans and ratio of different types of collagen), physical dimensions and mechanical properties can differ. Depending on the developmental stage of the tissue during which harvesting occurred, the microstructure can vary within an organism. Additionally, keeping in mind the size and shape of the final tissue, the potential of the physical dimensions of the tissue of origin must be considered. Despite this “memory” of the ECM tissue, methods have been engineered so that these innate characteristics can be modified, saved or removed. The modification process varies depending on the material used in clinical setting. Some ECM biomaterials undergo a modification that removes all the cells but leaves the remainder of the other ECM components called decellularization. Another process that can be introduced into the biomaterial is artificial crosslinking. Artificial crosslinking has been shown to stabilize reconstituted collagen, which can rapidly degenerate in vivo.
=== Warnings about dietary supplements === Between 2018 and 2023, the U.S. FDA issued 29 warning letters to American manufacturers of dietary supplements for making false claims of anti-disease effects from using products containing curcumin. In each letter, the FDA stated that the supplement product was not an approved new drug because the "product is not generally recognized as safe and effective" for the advertised uses, that "new drugs may not be legally introduced or delivered for introduction into interstate commerce without prior approval from FDA", and that the "FDA approves a new drug on the basis of scientific data and information demonstrating that the drug is safe and effective".
== A == Acinetobacter Acinetobacter baumannii Actinomyces Actinomyces israelii Actinomyces gerencseriae Agrobacterium radiobacter Agrobacterium tumefaciens Anaplasma Anaplasma phagocytophilum Anaplasma sparouinense Arcanobacterium haemolyticum Azorhizobium caulinodans Azotobacter vinelandii
According to this mechanism, dynorphin activates bradykinin receptors, which triggers the release of calcium ions into the cell through voltage-sensitive channels in the cell membrane. Blocking bradykinin receptors in the lumbar region of the spinal cord reversed persistent pain. A multiple pathway system might help explain the conflicting effects of dynorphin in the CNS. Svensson et al. provided another possible mechanism by which dynorphin might cause pain in the spinal cord. The authors found that administration of truncated dynorphin A2-17, which does not bind to opioid receptors, causes an increase in phosphorylated p38 mitogen-activated protein kinases (MAPK) in microglia in the dorsal horn of the spinal cord. Activated p38 has been previously linked to the NMDA-evoked prostaglandin release, which causes pain. Thus, dynorphin could also induce pain in the spinal cord through a non-opioid p38 pathway. Other studies have identified a role for dynorphin and KOR stimulation in neuropathic pain. This same group also showed that the dynorphin-KOR system mediates astrocyte proliferation through the activation of p38 MAPK that was required for the effects of neuropathic pain on analgesic responses. Taken together, these reports suggest that dynorphin can elicit multiple effects on both KOR, and non-opioid pathways to modulate analgesic responses.
Sources: en.wikipedia.org
Thirdly, succinylcholine use has been associated with postoperative myalgia, where patients often experience muscle pain similar to that of post-exercise muscle pain mainly in the shoulders, neck, neck and upper abdominal muscle the following day after surgery, especially in young healthy patients with greater muscle mass, whereas reports from children, elderly and pregnant woman are less frequent. This is caused by the fasciculations (muscle twitches) that appear in sites such as intercostal muscles, and the diaphragm. These fasciculations are not relieved through analgesics, and in common practice, a sub-paralyzing dose of non-depolarizing neuromuscular blocker is administered a few minutes before succinylcholine administration to reduce visible fasciculation and postoperative myalgia. The use of succinylcholine is therefore also contraindicated in patient with muscle myopathy within 24 to 72 hours post-administration. Non-depolarizing drug Atracurium: Atracurium is commonly associated with histamine-related symptoms, most notably flushing and erythema. Less commonly seen adverse effects include urticaria, hypotension, wheezing, tachycardia, bronchospasm, dyspnea, bradycardia, and laryngospasm. Moreover, drops of up to 30 mmHg in mean arterial pressure was also observed within two minutes of administration in some patients. H1 and H2 receptor blocking agents can be used to attenuate the drop in mean arterial pressure. A slow injection speed between 30 and 60 seconds reduces adverse effects.
Chronic Somogyi rebound is a contested explanation of phenomena of elevated blood sugars experienced by diabetics in the morning. Also called the Somogyi effect and posthypoglycemic hyperglycemia, it is a rebounding high blood sugar that is a response to low blood sugar. When managing the blood glucose level with insulin injections, this effect is counter-intuitive to people who experience high blood sugar in the morning as a result of an overabundance of insulin at night. This theoretical phenomenon was named after Michael Somogyi [suh MOE jee], a Hungarian-born professor of biochemistry at the Washington University and Jewish Hospital of St. Louis, who prepared the first insulin treatment given to a child with diabetes in the US in October 1922. Somogyi showed that excessive insulin makes diabetes unstable and first published his findings in 1938. Compare with the dawn phenomenon, which is a morning rise in blood sugar in response to waning insulin and a growth hormone surge (that further antagonizes insulin).
Features of the Initial Lesion: Vasculitis of vessels subjacent to junctional epithelium Increased migration of leukocytes into junctional epithelium Extravascular presence of serum proteins, especially fibrin Alteration of the most coronal portion of junctional epithelium Loss of perivascular collagen
Abdominal exercise Burpee (exercise) Calf raises Crunches Dips Hyperextensions Jumping jacks Leg raises Lunges Muscle-ups Plank Pull-ups Push-ups Sit-ups Squat jumps (Toyotas/box jumps) Squats Additional calisthenics exercises that can support the muscle groups –
AD 250) gives one of the earliest references regarding the plausible centenarian longevity given by a scientist, the astronomer Hipparchus of Nicaea (c. 185 – c. 120 BC), who, according to the doxographer, said that the philosopher Democritus of Abdera (c. 470/460 – c. 370/360 BC) lived 109 years. Other ancient accounts of Democritus agree that the philosopher lived at least 90 years. The case of Democritus differs from those of, for example, Epimenides of Crete (7th and 6th centuries BC), who is said to have lived an implausible 154, 157, or 290 years, depending on the source. Other ancient Greek philosophers thought to have lived beyond the age of 90 include Xenophanes of Colophon (c. 570/565 – c. 475/470BC), Pyrrho of Ellis (c. 360 – c. 270 BC), Gorgias of Leontinoi, and Eratosthenes of Cirene (c. 285 – c. 190 BC). Also, the Greek rhetorician Isocrates of Athens (436–338 BC) lived 97/98 years and the famous Greek tragedian Sophocles (497/496-406/405 BC) lived at least 90 years. Hosius of Córdoba, the man who convinced Constantine the Great to call the First Council of Nicaea, reportedly lived to age 102. A rare record of an ordinary person who lived to be a centenarian is the tombstone of Roman British legionary veteran Julius Valens, inscribed "VIXIT ANNIS C". It is believed the 7th century Pope Agatho lived to 103-104, making him the longest lived pope to this day as well as the only pope to become a centenarian. In the medieval period, Albert Azzo II, Margrave of Milan (d. 1097) is said by Bernold of Constance to have lived past 100 years (iam maior centenario).
Sources: en.wikipedia.org
Reversed-phase high-performance liquid chromatography with ultraviolet detection at 214 nanometres is the usual approach. Peak area percentage provides a purity figure relative to other components in the sample. Mass spectrometry is then applied to confirm identity.
Aspartate can cyclise into a succinimide intermediate that later hydrolyses back as isoaspartate. Both forms share the same molecular mass, so mass spectrometry alone cannot tell them apart. This shapes how purity data should be interpreted.
Freeze-dried material is normally kept desiccated below minus twenty degrees Celsius and shielded from light. Solutions are prepared shortly before use and held cold. Repeated thawing is avoided because it accelerates aggregation and degradation.
Mass spectrometry provides the identity check, because the observed mass is compared with the theoretical mass of the AEDG sequence. Chromatography separates and quantifies impurities but does not by itself prove which peptide is present. The two techniques are normally used together.